Filtered By:
Vaccination: Varicella-Zoster Virus Vaccine

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 265 results found since Jan 2013.

Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition
Our objective was to develop comprehensive national estimates of the total burden of herpes zoster (HZ) among U.S. adults, including direct (ie, medical costs) and indirect (ie, productivity losses) costs, as well as its psychosocial impact (ie, quality of life losses). Using a patient-level microsimulation model, we projected health and economic outcomes among U.S. adults aged 18 years and older using a 10-year time horizon. We conducted a comprehensive systematic literature review to generate parameter values and conducted simulation modeling to generate our outcomes, including numbers of cases of uncomplicated HZ, posth...
Source: Pain - January 23, 2020 Category: Anesthesiology Tags: Research Paper Source Type: research

Herpes zoster vaccine reduces chances of shingles after stem cell transplants
This NIHR Signal says that the risk of shingles is about 10% per year in adults after autologous stem cell transplant. The evidence summary indicates that two doses of deactivated herpes zoster vaccine could be a safe and effective way to reduce that risk by about two thirds.This effect is similar to another, heat-treated, non-live vaccine. Either vaccine could reduce the pain and need for medical treatment associated with shingles, and long-lasting complications such as post-herpetic neuralgia. It ' s not yet known if people need to continue taking acyclovir as well.
Source: Current Awareness Service for Health (CASH) - November 20, 2019 Category: Consumer Health News Source Type: news

Immunogenicity, Safety, and Tolerability of Live Attenuated VaricellaZoster Virus Vaccine (ZOSTAVAX ™) in Healthy Adults in India.
Conclusions: In healthy Indians ≥50 years, ZOSTAVAX was well tolerated and resulted in expected VZV-specific antibody titer levels at 6 weeks post-vaccination. PMID: 31325263 [PubMed - in process]
Source: Journal of the Association of Physicians of India - July 22, 2019 Category: General Medicine Tags: J Assoc Physicians India Source Type: research

Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention.
CONCLUSIONS: Overall, ZVL was 65% effective against PHN. It was effective in all age groups and provided moderate protection through 8 years. PMID: 31301920 [PubMed - as supplied by publisher]
Source: Vaccine - July 9, 2019 Category: Allergy & Immunology Authors: Klein NP, Bartlett J, Fireman B, Marks MA, Hansen J, Lewis E, Aukes L, Saddier P Tags: Vaccine Source Type: research

Therapy of herpes zoster and postherpetic neuralgia.
Authors: Hüning S, von Dücker L, Kohl WK, Nashan D Abstract Herpes zoster (HZ) is caused by the reactivation of varicella zoster virus. The incidence of herpes zoster and associated problems increases with age. With a life-long prevalence of 30%, every second 85-year-old person experiences HZ once in his lifetime. Three therapeutic columns are based on antiviral, topical and analgetic therapies. An extreme handicap is acute and persistent pain which can develop into postherpetic neuralgia (PHN). Those pain symptoms are predominantly neuropathic. The management of acute and chronic manifestation of pain may be cha...
Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - July 5, 2019 Category: Dermatology Tags: Hautarzt Source Type: research

Shingrix for Herpes Zoster: A Review
Abstract Herpes zoster (HZ), also known as shingles, results from reactivation of the latent varicella-zoster virus (VZV), which commonly causes chickenpox in childhood. Greater than 90% of adults are infected with this virus, putting them at risk for reactivation. HZ presents as a painful, vesicular rash distributed in a unilateral and dermatomal pattern along dorsal root or cranial nerve ganglia. The rash often presents with prodromal symptoms and progresses to include clear vesicular clusters, evolving through stages of pustulation, ulceration, and crusting. HZ therapy currently involves the use of antiviral ag...
Source: Skin Therapy Letter - June 30, 2019 Category: Dermatology Authors: Shah RA, Limmer AL, Nwannunu CE, Patel RR, Mui UN, Tyring SK Tags: Skin Therapy Lett Source Type: research

Herpes Zoster Vaccine
This article aimed to review the epidemiology, pathophysiology and complications of herpes zoster and mention the efficacies and problems of the live-attenuated and the new recombinant herpes zoster vaccines.PMID:31105132 | DOI:10.2222/jsv.68.21
Source: Uirusu. Journal of Virology - May 21, 2019 Category: Virology Authors: Daisuke Watanabe Source Type: research

Neurological and Ophthalmological Manifestations of Varicella Zoster Virus
Conclusions: HZ produces a spectrum of potentially blinding and life-threatening complications that adversely affect quality of life and increase health care costs. Individuals at risk for HZ, such as the elderly and immunocompromised, should be encouraged to receive the highly effective VZV vaccine to prevent HZ and its complications.
Source: Journal of Neuro-Ophthalmology - May 21, 2019 Category: Opthalmology Tags: State-of-the-Art Review Source Type: research

Herpes infection of the cornea
The clear tissue at the front of the eye is known as the cornea, and it must remain crystal clear in order for an individual to see clearly. The herpes viruses can infect the cornea, causing damage to tissue and possibly causing lasting visual impairment if not quickly identified and treated. Herpes simplex: the cold sore virus One of the most common infections of the cornea is caused by the herpes simplex virus (HSV type I and HSV type II), or the cold sore virus. The most common question from patients with HSV infection of the cornea is “How did I get this?” The answer is fairly simple. The virus is everywhere, and e...
Source: Harvard Health Blog - May 20, 2019 Category: Consumer Health News Authors: Emma Davies, MD Tags: Eye Health Infectious diseases Source Type: blogs

Gene Therapy Leaves a Vicious Cycle
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - April 23, 2019 Category: Cancer & Oncology Source Type: research

Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018.
Abstract Recombinant zoster vaccine (RZV; Shingrix), an adjuvanted glycoprotein vaccine, was licensed by the Food and Drug Administration (FDA) and recommended by the Advisory Committee on Immunization Practices for adults aged ≥50 years in October 2017 (1). The previously licensed live-attenuated zoster vaccine (ZVL; Zostavax) is recommended for adults aged ≥60 years. RZV is administered intramuscularly as a 2-dose series, with an interval of 2-6 months between doses. In prelicensure clinical trials, 85% of 6,773 vaccinated study participants reported local or systemic reactions after receiving RZV, with appr...
Source: MMWR Morb Mortal Wkl... - February 1, 2019 Category: Epidemiology Authors: Hesse EM, Shimabukuro TT, Su JR, Hibbs BF, Dooling KL, Goud R, Lewis P, Ng CS, Cano MV Tags: MMWR Morb Mortal Wkly Rep Source Type: research

Viruses, Vol. 11, Pages 103: Current In Vitro Models to Study Varicella Zoster Virus Latency and Reactivation
orbolla Varicella zoster virus (VZV) is a highly prevalent human pathogen that causes varicella (chicken pox) during primary infection and establishes latency in peripheral neurons. Symptomatic reactivation often presents as zoster (shingles), but it has also been linked to life-threatening diseases such as encephalitis, vasculopathy and meningitis. Zoster may be followed by postherpetic neuralgia, neuropathic pain lasting after resolution of the rash. The mechanisms of varicella zoster virus (VZV) latency and reactivation are not well characterized. This is in part due to the human-specific nature of VZV that preclude...
Source: Viruses - January 26, 2019 Category: Virology Authors: Nicholas L. Baird Shuyong Zhu Catherine M. Pearce Abel Viejo-Borbolla Tags: Review Source Type: research

Evidence Based Recommendations for Supportive Care in Multiple Myeloma
Conclusion:Along with anti-myeloma chemotherapy therapy, management of complications (anemia, infections, renal insufficiency) and other associated symptoms is necessary to improve the quality of life.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Qureshi, A., Tariq, M. J., Shah, Z., Abu Zar, M., Aslam, S., Rafae, A., Malik, M. N., Kamal, A., Jose, J. A., Selene, I. I., Shafqat, M., Jamil, F., Durer, S., Durer, C., Anwer, F. Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster I Source Type: research

Recombinant Zoster Vaccine (Shingrix ® ): A Review in Herpes Zoster
AbstractShingrix® is a recombinant zoster vaccine (RZV) that contains a varicella zoster virus glycoprotein  E antigen and the AS01B adjuvant system. The subunit vaccine is approved for the prevention of herpes zoster (HZ) [EU, USA, Japan, Canada and Australia] and postherpetic neuralgia (PHN) [EU and Australia] in adults aged  ≥ 50 years. In the pivotal trials in adults aged ≥ 50 years (ZOE-50) and ≥ 70 years (ZOE-70), RZV significantly reduced the risk of HZ and PHN. Its protective efficacy waned minimally over 4 years and was well preserved in adults aged ≥ 70 years. In patients with brea...
Source: Drugs and Aging - October 29, 2018 Category: Geriatrics Source Type: research

Modalities in managing postherpetic neuralgia.
Authors: Shrestha M, Chen A Abstract Postherpetic neuralgia (PHN) is the most troublesome side effect of Herpes Zoster (HZ), which mainly affects the elderly and immunocompromised populations. Despite the current advancement of treatments, PHN persists in many individuals influencing their daily activities and reducing their quality of life. Anticonvulsants, antidepressants, topical therapies including lidocaine and capsaicin, and opioids, are the most widely used therapies for the treatment of PHN. These medications come with their adverse effects, so they should be used carefully with the elderly or with patients...
Source: Korean Journal of Pain - October 13, 2018 Category: Anesthesiology Tags: Korean J Pain Source Type: research